EMA To Sit In On French FAAH Inhibitor Inquiry Meeting
This article was originally published in Scrip
Executive Summary
A senior official of the European Medicines Agency is to be an observer on the new French committee set up to look at the preclinical and clinical characteristics of FAAH inhibitors following the death of one volunteer and the hospitalization of several others during a Phase I study of Bial's BIA 10-2474.